Information Provided By:
Fly News Breaks for January 4, 2018
INSM
Jan 4, 2018 | 09:26 EDT
Stifel analyst Adam Walsh said additional interim data released by Insmed last night from its Pahse 3 program for Amikacin Liposome Inhalation Suspension, or ALIS, for adult patients with treatment refractory NTM lung disease "further bolsters" his "already high confidence" in the drug's chance for approval and commercial success. The analyst, who also noted that he does not see the company needing to raise capital in the near-term, keeps a Buy rating and $43 price target on Insmed shares.
News For INSM From the Last 2 Days
INSM
INSM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.